HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

der to reduce the incidence and severity of infusion-related adverse events. Patients also received prophylactic anti-infective treatment to reduce the risk of opportunistic infections. The primary endpoint for this trial was overall response rate (complete and partial response), and the study objective was to demonstrate a major response rate of at least 20 percent. Response rate was assessed by an independent review panel in accordance with the National Cancer Institute's guidelines for the diagnosis and treatment of CLL.

Of 93 evaluable patients, 31 demonstrated an objective response to treatment, for an overall response rate of 33%. Two of these responses were complete (2%) and 29 were partial responses (31%). Another 55 (59%) patients had disease stabilization. Median survival time has not yet been reached at about 10 months after the last patient was enrolled.

The safety profile of CAMPATH was consistent with that seen in previous studies and was judged by the investigators to be acceptable in this group of endstage CLL patients.

Adverse effects associated with CAMPATH in this study of 93 patients were mostly mild to moderate infusion-related symptoms. Severe (grade 3 and 4) infusion-related symptoms included: fever (13%), rigors (11%), dyspnea (6%), and hypotension (1%). During the study patients developed severe (grade 3 and 4) thrombocytopenia (low platelet count, 51%) or neutropenia (low white blood cell count, 61%) that usually improved within two months post-therapy. Some patients entering the study with severe (grade 3 and 4) thrombocytopenia and neutropenia improved to grade 2 or better within two months post-therapy: thrombocytopenia -- 7 of 19 (37%) patients improved,neutropenia -- 11 of 17 (65%) patients improved.

No unexpected serious adverse events were reported. The incidence of serious infections was reported to be 20% on this trial. It should be noted that infection is a common complication and cause of death
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:9/2/2015)... ... 2015 , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, ... consecutive year. Less than 5 % of this year’s 5000 honorees share the “six-time” ... Pentec’s 3-year revenue growth rate of 65% sustained its most recent achievement. As an ...
(Date:9/2/2015)... ... September 02, 2015 , ... Dr. Robert G. ... he is now certified in “Systema”: a Russian martial art system that is also ... , Systema , which dates back to the 10th century, is a ...
(Date:9/2/2015)... ... September 02, 2015 , ... Mobile working is increasingly more important, as business ... everywhere new mobile apps are being launched, and mobile device usage as a whole ... of their work and personal lives. What's more people are expecting mobile versions of ...
(Date:9/1/2015)... Spring Lake, NJ (PRWEB) , ... September 01, ... ... physician, has a reputation for the telling the truth about medicine and health, ... has created a video blog, where he plans to regularly debunk certain misconceptions ...
(Date:9/1/2015)... Paul- Eagan (PRWEB) , ... September 01, 2015 , ... For many men, the first ... chin. Men were often forced to wear a looser fitting shirt with a collar ... their neck, sliding a finger between their collar and skin all day because it’s uncomfortable. ...
Breaking Medicine News(10 mins):Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. ... U.S. Representatives Michael C. Burgess , M.D., and ... the 21 st Century Cures Act, bipartisan legislation ... the United States Senate. ... Sciences members, department chairs, center directors, and leading researchers ...
(Date:9/1/2015)... 2015  Results from an interim analysis of ... 5g of idarucizumab enabled emergency surgery to be ... with dabigatran (Pradaxa ® dabigatran etexilate mesylate). The ... of dabigatran enabled patients to be urgently brought ... 1.7 hours between administration of idarucizumab and start ...
(Date:9/1/2015)... 1, 2015 Agena Bioscience TM today announced ... , a commercial and financial hub from which many biotech ... testing laboratories in mainland China . ... Bioscience,s global sales with almost sixty MassARRAY ® Systems ... will allow us to expand our reach and foster ...
Breaking Medicine Technology:U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Agena Bioscience Opens Office in Shanghai, China 2
Cached News: